EUVIMEDEUVIMED entdecken
Crossref

Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure

P Shi, W T Zhu, A Liang, J Wan, J W Fu, X P Wu

Acta Gastro Enterologica Belgica · 2022-12 · 85 (4) · 593-600

DOI: 10.51821/85.4.10728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Gastro Enterologica Belgica, 2022-12. Verfasst von P Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, End Stage Liver Disease, Hepatitis B. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and study aims: Glucocorticoid (GC) treatment for liver failure is controversial. This study sought to evaluate the efficacy and predictive factors of glucocorticoid therapy for hepatitis B virus-related acute-on-chronic liver failure (HBV- ACLF). Patients and methods: A total of 302 patients with HBV- ACLF were enrolled and categorized by treatment modality (GC vs. Control). Baseline characteristics, liver function, disease complications, and mortality were recorded. Univariate and multivariate analysis were used to identify predictive factors for HBV-ACLF-related mortality. Results: GC therapy significantly improved the 30- and 60-day mortality of HBV-ACLF patients (4.64% vs. 11.92%, P=0.022 and 16.56% vs. 25.83%, P=0.049 for the Control and GC groups, respectively) and GC was an independent prognostic factor for 30-day mortality (OR = 0.177, 95% CI 0.051-0.616, P = 0.007). However, enhanced survival was not associated with improved liver function. There were no significant differences in the incidence of complications (i.e., ascites, bacterial infection, encephalopathy, hepatorenal syndrome, and gastrointestinal bleeding) between the GC and Control groups (P >0.05), except that fungal infection occurred with higher frequency in the GC group (P = 0.037). A significant improvement in the 30-day survival associated with GC therapy was observed among patients

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute-On-Chronic Liver FailureEnd Stage Liver DiseaseHepatitis BHumansHepatitis B virusGlucocorticoidsPrognosisRetrospective StudiesSeverity of Illness Index

Stichwörter der Autor:innen

acute-on-chronic liver failuregluco- corticoidhepatitis B virusprognosis

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Zitieren

APA

Shi, P., Zhu, W. T., Liang, A., Wan, J., Fu, J. W., & Wu, X. P. (2022). Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure. Acta Gastro Enterologica Belgica, 85(4), 593-600. https://doi.org/10.51821/85.4.10728

Vancouver

Shi P, Zhu WT, Liang A, Wan J, Fu JW, Wu XP. Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure. Acta Gastro Enterologica Belgica. 2022;85(4):593-600. doi:10.51821/85.4.10728

BibTeX
@article{Shi2022,
  author = {Shi, P and Zhu, W T and Liang, A and Wan, J and Fu, J W and Wu, X P},
  title = {Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure},
  journal = {Acta Gastro Enterologica Belgica},
  year = {2022},
  volume = {85},
  number = {4},
  pages = {593--600},
  doi = {10.51821/85.4.10728}
}
Kostenlos starten →